Khalid O Dar, MD
- ASSISTANT PROFESSOR | Medicine, Hematology and Medical Oncology
- Cancer (Oncology)
- Urdu (Pakistan)
- Indian (Hindi)
- Hospital Affiliations
- Mount Sinai Beth Israel
- The Mount Sinai Hospital
- Mount Sinai Morningside and Mount Sinai West
- Mount Sinai Morningside 212-523-8570 212-523-8570
I have been on staff at St. Luke’s Hospital since 1995 and have dedicated almost my entire career in serving the patients and community of St. Luke’s. I was initially involved in training fellows in the Hematology/Oncology fellowship program at St. Luke’s Hospital and subsequently served as a voluntary attending physician in private practice.
I am proud of the affiliation with Mount Sinai particularly now that the Tisch Cancer Institute at Mount Sinai has received NCI designation as a Clinical Cancer Center. I have always been focused on providing personalized, compassionate care and now with the close association with Mount Sinai my patients will have access to the most up-to-date research, diagnostic tools and therapies available.
- Breast Cancer
- Colorectal Cancer
- Gastric (Stomach) Cancer
- Hematologic Malignancies
- Lung Cancer
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Pancreatic Cancer
- Prostate Cancer
MBBS, Westminster Medical School
Queen Mary's Hospital
Residency, Internal Medicine
Staten Island University Hospital
NYU Langone Medical Center
English, Urdu (Pakistan), Indian (Hindi)
As a fellow my research project focused on the drug development of the topoisomerase I inhibitor topotecan. Using Western Blot assays I quantified the topoisomerase I copy numbers in a variety of human tumors to identify potential cancers that may be susceptible to this therapy. I was also involved in developing a mouse in vivo system for combination immuno-chemotherapy using xenografts of human mammary tumors in mice.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Dar did not report having any of the following types of financial relationships with industry during 2021 and/or 2022: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.